Anti-TNK2 antibody (250-300) {FITC}

Cat# NB-22-56880-100

Size : 100ug

Brand : Neo Biotech

Request more information

Contact local distributor :


Phone : +1 850 650 7790

  • Western blot Immunoprecipitation with Anti-TNK2 Antibody (FITC) of solubilized COS1 cells expressing constitutively active ACK1at 1:500 dilution in buffer.

General Info

Host: Rabbit
Applications: ELISA/IP/WB
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-TNK2 (250-300) is suitable for use in ELISA, Immunoprecipitation and Western Blot research applications.
Clonality: Polyclonal
Conjugation: FITC
Isotype: IgG
Purification: Affinity Purified
Concentration: 0.59-0.68 µg/µl
Dilution Range: WB: 1:500
ELISA: 1:10, 000
IP: 1:200
Storage Instruction: Store at-20°C for long term storage. Avoid freeze-thaw cycles.

Information

Gene Symbol: TNK2
Gene ID: 10188
Uniprot ID: ACK1_HUMAN
Immunogen Region: 250-300
Immunogen: Synthetic peptide taken within amino acid region 300-400 on ACK1 protein.

Description

Tissue Specificity The Tyr-284 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages. It also shows a significant increase in expression in prostate cancers during the progressive stages.
Post Translational Modifications Autophosphorylation regulates kinase activity. Phosphorylation on Tyr-518 is required for interaction with SRC and is observed during association with clathrin-coated pits. Polyubiquitinated by NEDD4 and NEDD4L. Degradation can be induced by EGF and is lysosome-dependent.
Function Non-receptor tyrosine-protein and serine/threonine-protein kinase that is implicated in cell spreading and migration, cell survival, cell growth and proliferation. Transduces extracellular signals to cytosolic and nuclear effectors. Phosphorylates AKT1, AR, MCF2, WASL and WWOX. Implicated in trafficking and clathrin-mediated endocytosis through binding to epidermal growth factor receptor (EGFR) and clathrin. Binds to both poly- and mono-ubiquitin and regulates ligand-induced degradation of EGFR, thereby contributing to the accumulation of EGFR at the limiting membrane of early endosomes. Downstream effector of CDC42 which mediates CDC42-dependent cell migration via phosphorylation of BCAR1. May be involved both in adult synaptic function and plasticity and in brain development. Activates AKT1 by phosphorylating it on 'Tyr-176'. Phosphorylates AR on 'Tyr-267' and 'Tyr-363' thereby promoting its recruitment to androgen-responsive enhancers (AREs). Phosphorylates WWOX on 'Tyr-287'. Phosphorylates MCF2, thereby enhancing its activity as a guanine nucleotide exchange factor (GEF) toward Rho family proteins. Contributes to the control of AXL receptor levels. Confers metastatic properties on cancer cells and promotes tumor growth by negatively regulating tumor suppressor such as WWOX and positively regulating pro-survival factors such as AKT1 and AR. Phosphorylates WASP.
Protein Name Activated Cdc42 Kinase 1
Ack-1
Tyrosine Kinase Non-Receptor Protein 2
Cellular Localisation Cell Membrane
Nucleus
Endosome
Cell Junction
Adherens Junction
Cytoplasmic Vesicle Membrane
Peripheral Membrane Protein
Cytoplasmic Side
Cytoplasmic Vesicle
Clathrin-Coated Vesicle
Membrane
Clathrin-Coated Pit
Cytoplasm
Perinuclear Region
Cytosol
The Tyr-284 Phosphorylated Form Is Found Both In The Membrane And Nucleus
Co-Localizes With Egfr On Endosomes
Nuclear Translocation Is Cdc42-Dependent
Detected In Long Filamentous Cytosolic Structures Where It Co-Localizes With Ctps1
Alternative Antibody Names Anti-Activated Cdc42 Kinase 1 antibody
Anti-Ack-1 antibody
Anti-Tyrosine Kinase Non-Receptor Protein 2 antibody
Anti-TNK2 antibody
Anti-ACK1 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance